Taiwan · Delayed Price · Currency is TWD PharmaEssentia Statistics
Total Valuation
PharmaEssentia has a market cap or net worth of TWD 255.73 billion. The enterprise value is 233.89 billion.
| Market Cap | 255.73B |
| Enterprise Value | 233.89B |
Important Dates
The last earnings date was Wednesday, February 25, 2026.
| Earnings Date | Feb 25, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
PharmaEssentia has 371.16 million shares outstanding. The number of shares has increased by 0.14% in one year.
| Current Share Class | 371.16M |
| Shares Outstanding | 371.16M |
| Shares Change (YoY) | +0.14% |
| Shares Change (QoQ) | +0.29% |
| Owned by Insiders (%) | 8.16% |
| Owned by Institutions (%) | 8.73% |
| Float | 294.21M |
Valuation Ratios
The trailing PE ratio is 50.70 and the forward PE ratio is 31.92.
| PE Ratio | 50.70 |
| Forward PE | 31.92 |
| PS Ratio | 16.36 |
| PB Ratio | 8.00 |
| P/TBV Ratio | 8.06 |
| P/FCF Ratio | 75.96 |
| P/OCF Ratio | 48.45 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 44.34, with an EV/FCF ratio of 69.48.
| EV / Earnings | 46.36 |
| EV / Sales | 14.96 |
| EV / EBITDA | 44.34 |
| EV / EBIT | 47.50 |
| EV / FCF | 69.48 |
Financial Position
The company has a current ratio of 6.20, with a Debt / Equity ratio of 0.03.
| Current Ratio | 6.20 |
| Quick Ratio | 5.84 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | 0.16 |
| Debt / FCF | 0.25 |
| Interest Coverage | 193.04 |
Financial Efficiency
Return on equity (ROE) is 16.97% and return on invested capital (ROIC) is 51.42%.
| Return on Equity (ROE) | 16.97% |
| Return on Assets (ROA) | 9.00% |
| Return on Invested Capital (ROIC) | 51.42% |
| Return on Capital Employed (ROCE) | 15.06% |
| Weighted Average Cost of Capital (WACC) | 5.57% |
| Revenue Per Employee | 119.35M |
| Profits Per Employee | 38.51M |
| Employee Count | 131 |
| Asset Turnover | 0.46 |
| Inventory Turnover | 1.29 |
Taxes
| Income Tax | -62.23M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +20.41% in the last 52 weeks. The beta is 0.24, so PharmaEssentia's price volatility has been lower than the market average.
| Beta (5Y) | 0.24 |
| 52-Week Price Change | +20.41% |
| 50-Day Moving Average | 603.29 |
| 200-Day Moving Average | 513.43 |
| Relative Strength Index (RSI) | 52.47 |
| Average Volume (20 Days) | 3,988,092 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, PharmaEssentia had revenue of TWD 15.63 billion and earned 5.05 billion in profits. Earnings per share was 13.59.
| Revenue | 15.63B |
| Gross Profit | 13.95B |
| Operating Income | 4.93B |
| Pretax Income | 4.98B |
| Net Income | 5.05B |
| EBITDA | 5.06B |
| EBIT | 4.93B |
| Earnings Per Share (EPS) | 13.59 |
Balance Sheet
The company has 22.69 billion in cash and 856.03 million in debt, with a net cash position of 21.84 billion or 58.84 per share.
| Cash & Cash Equivalents | 22.69B |
| Total Debt | 856.03M |
| Net Cash | 21.84B |
| Net Cash Per Share | 58.84 |
| Equity (Book Value) | 31.98B |
| Book Value Per Share | 86.15 |
| Working Capital | 24.36B |
Cash Flow
In the last 12 months, operating cash flow was 5.28 billion and capital expenditures -1.91 billion, giving a free cash flow of 3.37 billion.
| Operating Cash Flow | 5.28B |
| Capital Expenditures | -1.91B |
| Free Cash Flow | 3.37B |
| FCF Per Share | 9.07 |
Margins
Gross margin is 89.23%, with operating and profit margins of 31.52% and 32.27%.
| Gross Margin | 89.23% |
| Operating Margin | 31.52% |
| Pretax Margin | 31.87% |
| Profit Margin | 32.27% |
| EBITDA Margin | 32.37% |
| EBIT Margin | 31.52% |
| FCF Margin | 21.53% |
Dividends & Yields
This stock pays an annual dividend of 1.10, which amounts to a dividend yield of 0.16%.
| Dividend Per Share | 1.10 |
| Dividend Yield | 0.16% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 1 |
| Payout Ratio | 7.26% |
| Buyback Yield | -0.14% |
| Shareholder Yield | -0.00% |
| Earnings Yield | 1.97% |
| FCF Yield | 1.32% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on September 11, 2025. It was a forward split with a ratio of 1.10973093.
| Last Split Date | Sep 11, 2025 |
| Split Type | Forward |
| Split Ratio | 1.10973093 |
Scores
PharmaEssentia has an Altman Z-Score of 22.46 and a Piotroski F-Score of 7.
| Altman Z-Score | 22.46 |
| Piotroski F-Score | 7 |